About ReGen Therapeutics Limited
ReGen Therapeutics Limited (Company Registration No. 07476879) was originally a pharmaceutical development company but stopped research activity and the generation of revenue from licensing arrangements of it’s product Colostrinin several years ago.
Since then, shareholders have retained their holdings in the company while its directors, Timothy Shilton and Norman Lott, have been actively seeking the right opportunity to generate real value for those shareholders. That search led them to Futurum Group. To avoid any confusion with other businesses of a similar name, we want to be clear that ReGen Therapeutics Limited has no current involvement in pharmaceuticals, cancer research, drug development or medical treatments of any kind.
About Futurum Group
Futurum Group is a children's media and entertainment company already well on its way to success, with a portfolio of independently valued TV animation IPs, signed broadcaster contracts across 120+ countries with names including NBC Universal, Cartoonito and Netflix, and a clear pathway to a public listing on AIM or the London Stock Exchange later in 2026.
The merger brings together Futurum's momentum and IP with the capital raised through the ReGen Rights Issue, accelerating the machine and giving existing ReGen shareholders a meaningful stake in something with real global potential. Over 1,500 shareholders and external investors are already engaged in the merger process and the opportunity to invest in the merged company pre-IPO on generous terms.